Morgan Stanley’s NanoViricides NNVC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.61K Hold
2,616
﹤0.01% 7288
2026
Q1
$2.39K Sell
2,616
-16,035
-86% -$16.8K ﹤0.01% 7298
2025
Q4
$21.1K Buy
18,651
+16,704
+858% +$23.5K ﹤0.01% 6683
2025
Q3
$2.78K Hold
1,947
﹤0.01% 7235
2025
Q2
$2.73K Buy
1,947
+1,831
+1,578% +$2.5K ﹤0.01% 7164
2025
Q1
$136 Hold
116
﹤0.01% 7523
2024
Q4
$166 Sell
116
-145
-56% -$208 ﹤0.01% 7428
2024
Q3
$392 Sell
261
-1,000
-79% -$1.86K ﹤0.01% 7324
2024
Q2
$2.17K Buy
1,261
+1,024
+432% +$1.82K ﹤0.01% 7051
2024
Q1
$275 Hold
237
﹤0.01% 7286
2023
Q4
$242 Hold
237
﹤0.01% 7285
2023
Q3
$318 Hold
237
﹤0.01% 7354
2023
Q2
$273 Buy
237
+150
+172% +$181 ﹤0.01% 7427
2023
Q1
$102 Hold
87
﹤0.01% 7570
2022
Q4
$97 Sell
87
-23,682
-100% -$36.9K ﹤0.01% 7697
2022
Q3
$41K Buy
23,769
+23,646
+19,224% +$51.6K ﹤0.01% 6493
2022
Q2
$0 Sell
123
-637
-84% -$1.17K ﹤0.01% 7913
2022
Q1
$2K Sell
760
-543
-42% -$1.27K ﹤0.01% 7749
2021
Q4
$5K Sell
1,303
-2,150
-62% -$9.79K ﹤0.01% 7645
2021
Q3
$16K Buy
3,453
+1
+0% +$4 ﹤0.01% 7178
2021
Q2
$16K Hold
3,452
﹤0.01% 7073
2021
Q1
$16K Sell
3,452
-4,750
-58% -$21.5K ﹤0.01% 6801
2020
Q4
$24K Sell
8,202
-21,282
-72% -$77.5K ﹤0.01% 6378
2020
Q3
$113K Sell
29,484
-25,147
-46% -$138K ﹤0.01% 5370
2020
Q2
$409K Buy
54,631
+8,154
+18% +$56.7K ﹤0.01% 4705
2020
Q1
$267K Buy
46,477
+45,324
+3,931% +$320K ﹤0.01% 4745
2019
Q4
$3K Buy
1,153
+259
+29% +$585 ﹤0.01% 6465
2019
Q3
$2K Buy
894
+1
+0.1% +$4 ﹤0.01% 6484
2019
Q2
$4K Sell
893
-18
-2% -$92 ﹤0.01% 6355
2019
Q1
$5K Buy
911
+218
+31% +$1.42K ﹤0.01% 6324
2018
Q4
$3K Buy
693
+200
+41% +$1.28K ﹤0.01% 6378
2018
Q3
$4K Sell
493
-18
-4% -$139 ﹤0.01% 6479
2018
Q2
$5K Buy
511
+68
+15% +$835 ﹤0.01% 6438
2018
Q1
$7K Sell
443
-300
-40% -$5.55K ﹤0.01% 6340
2017
Q4
$13K Buy
743
+529
+247% +$10.8K ﹤0.01% 6177
2017
Q3
$5K Buy
+214
New +$5.75K ﹤0.01% 6294
2017
Q1
Sell
-24
Closed -$1K 6594
2016
Q4
$1K Hold
24
﹤0.01% 6448
2016
Q3
$1K Sell
24
-224
-90% -$7.42K ﹤0.01% 6432
2016
Q2
$8K Sell
248
-707
-74% -$25.8K ﹤0.01% 6109
2016
Q1
$42K Buy
955
+421
+79% +$16.3K ﹤0.01% 5681
2015
Q4
$13K Sell
534
-253
-32% -$6.06K ﹤0.01% 6177
2015
Q3
$19K Sell
787
-75
-9% -$1.99K ﹤0.01% 6064
2015
Q2
$30K Buy
862
+100
+13% +$3.81K ﹤0.01% 6023
2015
Q1
$35K Sell
762
-1,500
-66% -$80K ﹤0.01% 5904
2014
Q4
$123K Buy
2,262
+931
+70% +$61.6K ﹤0.01% 5463
2014
Q3
$80K Buy
1,331
+76
+6% +$5.97K ﹤0.01% 5561
2014
Q2
$106K Sell
1,255
-215
-15% -$15.3K ﹤0.01% 5472
2014
Q1
$94K Sell
1,470
-505
-26% -$43.2K ﹤0.01% 5475
2013
Q4
$189K Buy
+1,975
New +$203K ﹤0.01% 5056

Other funds holding NNVC

Morgan Stanley's NNVC Position: Q2 2026 in Review

Morgan Stanley held its NanoViricides (NNVC) position steady in Q2 2026 at 2,616 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #7288.

Morgan Stanley first reported a position in NNVC in Q4 2013 and has held it in 49 quarters since. The position peaked at $409K in Q2 2020. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2026.

  • Morgan Stanley held 2,616 shares of NanoViricides worth $3.61K as of Q2 2026.
  • Morgan Stanley left its NanoViricides share count unchanged in Q2 2026.
  • NanoViricides made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7288 holding.
  • Morgan Stanley first reported a position in NanoViricides in Q4 2013 and has held it in 49 quarters since.
  • Morgan Stanley's NanoViricides position peaked at $409K in Q2 2020.
  • 48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.